News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

26th Apr 22

Pharmaxis Quarterly Shareholder Update and Investor Briefing

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 29 April 2022.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Friday 29 April 2022.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

The event is free to attend, and investors should register in advance using the following registration link:  

https://www.pharmaxis.com.au/investor-centre/investor-briefing/

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au

Read full media release - pdf
1st Apr 22

Pharmaxis R&D Showcase Webinars - Recordings

Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods. 

Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers. 

Presentation

Speaker

Link to recording

Welcome and Introduction to Pharmaxis research and clinical development program

Michael Woods

Dr Wolfgang Jarolimek

Gary Phillips

https://youtu.be/Hi8xcf3vQS0

The myelofibrosis landscape and MF-101

Dr Gabriela Hobbs (Massachusetts General Hospital)

https://youtu.be/OCFEY-B8iNk

Hepatocellular cancer and Rochester University investigator led study

Dr Paul Burchard (Rochester NY)

https://youtu.be/mFipCvAay2Y

Pancreatic Cancer

Dr Tom Cox
(Garvan Sydney)

https://youtu.be/8nKVdkusdqo 

Pharmaxis Q&A

Gary Phillips

https://youtu.be/8BKY9WST2Qs

Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)

A pdf of the presentations is available here.

Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.

Presentation

Speaker

Link to recording

Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology

Gary Phillips

https://youtu.be/BcOm0ujKw3k

The science of scarring and potential for LOX inhibition

Dr Mark Fear (UWA)

https://youtu.be/AYy7M932O4M

Clinical applications for LOX inhibition

Professor Fiona Wood (UWA)

https://youtu.be/kMjZkuLjfr0

Q&A with panel

 

https://youtu.be/kQOWIGbKrF8

Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)

A pdf of the presentations is available here.

18th Mar 22

Pharmaxis Investor R&D Showcase Webinars

Clinicians to Speak About Pharmaxis Programs

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) will host R&D showcase webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs will be followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers.

Pharmaxis drug PXS-5505 targeting several cancers:

Date & time: 29 March 2022 at 11.00am (AEDT)

Speakers:

  • Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
  • Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
  • Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research

To register for this event please use the following link: https://zoom.us/webinar/register/WN_B8Te020aTUqyb2A3H93saA

 Pharmaxis drug PXS-6302 targeting scarring:

Date & time: 31 March 2022 at 11.00am (AEDT)

Speakers:

  • The science of scarring and potential for LOX inhibition - Dr. Mark Fear, Senior Research Fellow University of Western Australia
  • Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia

To register for this event please use the following link: https://zoom.us/webinar/register/WN_66zxZbVsRm-GCocT8_NiAQ

 The webinars are free to attend and a recording of the events will be made available on the Pharmaxis website. 

Read full media release - pdf